Related Experiment Videos

Efficacy and adverse effects of nateglinide in early type 2 diabetes. Comparison with voglibose in a cross-over study

Shogo Kurebayashi1, Hirotaka Watada, Yasushi Tanaka

  • 1Department of Internal Medicine, Nishinomiya Municipal Central Hospital, Japan.

Endocrine Journal
|April 19, 2006
PubMed

Insights

Nateglinide and voglibose effectively lowered HbA1c in early type 2 diabetes patients. Nateglinide was favored due to fewer gastrointestinal side effects compared to voglibose.

Area of Science:

  • Endocrinology
  • Pharmacology
  • Metabolic Diseases

Background:

  • Type 2 diabetes mellitus (T2DM) is a growing global health concern.
  • Early management of T2DM is crucial to prevent long-term complications.
  • Oral hypoglycemic agents are a cornerstone of T2DM treatment.

Purpose of the Study:

  • To compare the efficacy and safety of nateglinide versus voglibose in Japanese patients with early type 2 diabetes.
  • To evaluate glycemic control and adverse events associated with each drug.

Main Methods:

  • An open-label, prospective, cross-over trial was conducted.
  • 14 patients received nateglinide (270 mg/day) and 15 received voglibose (0.6 mg/day) for 12 weeks each.
  • Patients were switched to the alternative drug for a subsequent 12-week period.

Main Results:

  • Both nateglinide and voglibose significantly reduced HbA1c levels (p<0.01 and p<0.05, respectively).
  • No significant difference in HbA1c reduction was observed between the two drugs (p=0.121).
  • Hypoglycemic symptoms were rare; however, voglibose was associated with more frequent abdominal fullness/borborygmi than nateglinide.

Conclusions:

  • Nateglinide and voglibose demonstrate comparable efficacy in improving glycemic control in early type 2 diabetes.
  • Nateglinide appears to be a safe and effective alternative, potentially with a better gastrointestinal tolerability profile than voglibose.

Related Concept Videos

Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: &#945;-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis01:25

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...